Maximus review 2026: the men's performance-medicine play, examined

Maximus is a privately held cash-pay telehealth platform positioned as a "performance medicine" company for men. The brand language ("performance medicine," "human potential," "make optimal your new normal") is positioned more toward the optimization end of the wellness spectrum than the medical-treatment end — closer to high-performance athletic medicine than to standard primary-care framing. The platform is not publicly traded and does not file with the SEC.

The company self-reports 50,000+ members — meaningfully smaller than Ro's 3M+ claim or Mochi's 500k+ claim, and orders of magnitude below Hims's 2.4M+. Maximus is the smallest by member count of the larger-platform providers in our set, though materially larger than TrimRx by Trustpilot proxy.

The product breadth is unusual. Where every other provider in our set leads with weight loss (GLP-1) and treats testosterone as a sideline (or doesn't carry it at all), Maximus reverses the priority. Testosterone is the primary category. The platform offers four delivery formats — testosterone cream, injectable testosterone, oral testosterone, and enclomiphene capsules. GLP-1 (tirzepatide and semaglutide) is a substantial second category but secondary. Additional categories include a patent-pending Oxytocin Calming Cream marketed for mood, stress, and sleep; growth hormone peptides including sermorelin; lab testing (a 146-marker comprehensive panel and a 10-marker at-home testosterone test); ED treatments (vardenafil, tadalafil, sildenafil); and an "All-in-One Gel" for hair growth.

The CEO and Co-Founder is foregrounded across the site with the "Dr." honorific. The title rests on a PhD in Clinical Psychology — described as Harvard-educated and a former Assistant Clinical Professor of Psychiatry at UCSF School of Medicine. Technically correct for a PhD-holder, but bears foregrounding for patients: this is not an MD credential, and the executive is not a prescribing physician. The clinical-business leadership and the prescribing physician roles are distinct.

Maximus's pricing is partially published on the homepage — GLP-1 entry rates and Oxytocin Calming Cream — but the full testosterone, peptide, ED, and lab matrices live behind the per-protocol pages and the onboarding flow. The static surface shows representative entry rates rather than complete ladders.

Pricing on the static surface (accessed 10 June 2026). Multi-month commitments, paid-in-full discounts, and full per-protocol ladders sit inside the per-protocol pages and the onboarding flow rather than the homepage. Re-verification before signup recommended; we update this page when prices change.

Weight loss (GLP-1)

Mood, stress, sleep

Testosterone, growth hormone peptides, ED, lab testing

Specific pricing for testosterone protocols (cream, injectable, oral, enclomiphene), growth hormone peptides (sermorelin and others), ED medications (vardenafil/tadalafil/sildenafil), and lab panels was not on the static homepage at the time of this review. These require per-protocol page fetches or onboarding-flow entry. We've listed this as an open item — the full Maximus ladder belongs in a later pricing-focused update.

Insurance / FSA / HSA. Maximus explicitly states it "doesn't require insurance" and operates on transparent direct-pay pricing. Insurance is not accepted. FSA/HSA acceptance is not specifically advertised on the homepage and warrants verification at signup. No Klarna/Affirm/Afterpay options were observed in the static surface.

Maximus's funnel is broadly the cash-pay-telehealth template with two distinctive features.

Online health questionnaire. Detailed intake covering goals, history, and current medications.

Online physician consultation. A Maximus physician reviews the information 100% online and determines the appropriate protocol. The consultation model — synchronous, asynchronous, or hybrid — is not specified on the homepage; per-protocol pages and onboarding screens may clarify.

Lab work from home (if needed). Maximus operates a "deeper insights" lab layer through Maximus Labs (separate from the standard at-home testosterone test). The 146-marker comprehensive panel is offered as part of testosterone-protocol onboarding when clinically appropriate.

Personalized protocol. Medications, supplements, and "lifestyle guidance" shipped in discreet, secure packaging.

Care team check-ins. Track progress, doctor-led adjustments as needed.

Discord community. Maximus operates an official Discord (linked from the homepage) for community engagement. This is unusual in the medical-DTC space and reflects the platform's positioning toward the men's-optimization community rather than the standard primary-care framing.

Quoted timelines (intake to shipment) are not on the homepage. Open Item.

Maximus's headline outcome visualizations — "↑3.1× Free testosterone, 382 → 1180" for testosterone and "↓28% body fat over 18 months" for weight loss — are presented in clinical-trial-style chart formats but are not footnoted to any peer-reviewed source. They are uncited company-marketing graphics. Under our editorial standards, claims of this kind are recorded as what the company says but not propagated as evidence.

The underlying evidence base for what Maximus's offerings can do exists in the peer-reviewed literature, just not in Maximus's own publications.

Testosterone replacement therapy (general). The most current cardiovascular-safety primary trial is TRAVERSE (Lincoff AM et al., NEJM 2023), which assessed cardiovascular outcomes in middle-aged and older men receiving testosterone replacement. Standard testosterone-therapy literature also includes meta-analyses of muscle mass, bone density, mood, and sexual function endpoints. FDA-approved branded testosterone products include Depo-Testosterone (cypionate injection, NDA 085635, 1979), AndroGel (topical, NDA 021015, 2000), and KYZATREX (oral, NDA 215312, Marius Pharmaceuticals, 2022). The clinical evidence base for branded testosterone-replacement therapy is substantial.

Enclomiphene as TRT alternative. Enclomiphene is the trans-isomer of clomiphene citrate. Clomiphene is FDA-approved as Clomid for fertility treatment in women. Enclomiphene is not FDA-approved as a standalone therapy for any indication. Its use for elevating endogenous testosterone in men is off-label with preliminary, primarily early-phase trial evidence — there is no Phase 3 trial program demonstrating long-term cardiovascular safety or outcome equivalence to FDA-approved TRT. Maximus offers enclomiphene as part of its TRT menu but does not foreground the off-label status for patients.

Compounded GLP-1. For semaglutide and tirzepatide, the relevant Tier A trials are STEP 1 (14.9% mean weight loss at 68 weeks) and SURMOUNT-1 (~20%+ at higher tirzepatide doses over 72 weeks). All studied branded, FDA-approved versions. Maximus dispenses compounded versions — same caveats apply as at other compounded-DTC providers in our set.

Oxytocin Calming Cream. This is the platform's most novel product. Oxytocin is an FDA-approved drug (Pitocin) for labor induction. Transdermal compounded oxytocin formulations for mood, stress, and sleep are off-label and not FDA-reviewed for any of those indications. The peer-reviewed evidence for intranasal oxytocin in social anxiety has been mixed (Quintana et al., Lancet Psychiatry meta-analyses); transdermal-delivery-specific evidence for mood/stress/sleep outcomes is sparse. Maximus's outcome claims for the cream — improved happiness, sleep satisfaction, reduced anxiety, more sleep per night — are footnoted to a Maximus-published whitepaper ("A Novel Oxytocin Formulation for Mood, Stress, and Sleep") that meets all four exclusion criteria under our editorial standards (Maximus-employee authorship, study population on Maximus's own platform, no independent control, publication venue not peer-reviewed). We record this as a marketing observation; we do not propagate the outcome claims as evidence.

Sermorelin and growth hormone peptides. Sermorelin is not FDA-approved as a drug; it is commonly compounded for off-label growth hormone support. Peer-reviewed evidence for sermorelin in adults is limited — most published research is in pediatric growth hormone deficiency.

PDE5 inhibitors (sildenafil, tadalafil, vardenafil). FDA-approved and well-established.

Testosterone replacement therapy carries documented risks including erythrocytosis (elevated red blood cell mass), prostate hypertrophy, sleep apnea exacerbation, gynecomastia, and reduced fertility from suppression of endogenous testosterone production. Cardiovascular safety in middle-aged and older men was addressed in TRAVERSE, which found no significant increase in major adverse cardiovascular events vs. placebo. However, individual risk varies and ongoing monitoring through lab work is standard.

Anastrozole (an aromatase inhibitor included with most Maximus testosterone protocols) carries its own safety profile including reduced bone mineral density and lipid changes — appropriate monitoring is required.

Enclomiphene is off-label for testosterone elevation in men. Long-term safety data is limited.

Compounded GLP-1 carries the same class-level risks as branded (GI side effects, pancreatitis, gallbladder problems, thyroid C-cell tumor boxed warning, pregnancy contraindication) plus the additional compounded-product quality concerns documented in FDA FAERS (elevated AE rates and potency errors).

Compounded oxytocin (transdermal) has limited safety profile data for the mood/stress/sleep use case. Standard hormonal medication precautions apply, but the specific transdermal-mood formulation Maximus dispenses is not the subject of any FDA-reviewed safety dataset.

Maximus operates a substantial lab-testing layer alongside the protocols, which is the right approach for testosterone management. The platform's focus on baseline labs before treatment and follow-up labs during treatment is medically appropriate, even if the company-stated outcome statistics built on top of those labs are not independently verifiable.

Anyone considering Maximus should be eyes-open about: the off-label status of enclomiphene as TRT, the experimental nature of the transdermal oxytocin cream for mood/stress, and the compounded status of the GLP-1 line.

Maximus's exposure to the FDA's GLP-1 compounding regulatory squeeze parallels other compounded-DTC providers. The FDA timeline — semaglutide and tirzepatide removed from shortage (Dec 2024 / Feb 2025), 503A and 503B grace periods ending in April and May 2025, the 503B Bulks List exclusion proposal of April 2026, and the public-comment deadline of 29 June 2026 — applies to Maximus's compounded GLP-1 line.

On the marketing side of that same squeeze, Maximus is now also one of the named recipients in the FDA's June 8, 2026 enforcement batch against telehealth platforms selling compounded GLP-1s. The letter (MARCS-CMS 730095, signed by Matthew J. Lash, JD, Acting Director of the Office of Compounding Quality and Compliance) does not address Maximus's testosterone, oxytocin, sermorelin, or any non-GLP-1 product — it is narrowly about four phrases on the weight-loss page. Two of the four ("Clinically studied ingredients," "Clinically studied to help patients…") implicate the company's habit of citing self-published whitepapers as if they were independent evidence — the exact pattern we already excluded under our editorial source-hierarchy rule for self-published studies. The third ("Proven to lose weight effectively") is the kind of unqualified efficacy claim that compounded products, by FDA's definition, cannot make. The fourth ("FDA approved pharmacies") is the most common pattern in the entire June 8 batch: marketing copy on telehealth sites that conflates an outsourcing facility's voluntary FDA registration with actual FDA approval, which the FD&C Act does not establish for compounders. The full analysis of the four claim patterns FDA cited across the batch is in our news story.

Beyond GLP-1, Maximus is exposed to a different regulatory landscape that the other providers in our set don't share. Testosterone is a Schedule III controlled substance. Prescribing requires DEA registration. Compounded testosterone products are more regulated than compounded GLP-1, with state-pharmacy-board oversight on every batch. Maximus's compounded testosterone formats (cream, injection, oral) operate inside that framework.

Enclomiphene is not FDA-approved as a drug. Maximus's compounded enclomiphene capsules operate under the standard 503A compounding allowance for individualized prescriptions, but the underlying drug has no FDA-approved label for the use Maximus prescribes it for.

Sermorelin is also not FDA-approved as a drug for adult growth-hormone support; compounded for off-label use under standard 503A regulation.

Oxytocin Calming Cream is "patent-pending" per Maximus's own copy. A patent application is not the same as a granted patent. The formulation is also not FDA-approved for mood/stress/sleep indications.

Maximus's pharmacy partner language: "We strictly partner with US-based, fully licensed compounding pharmacies that operate in compliance with rigorous USP standards for sterility and quality assurance. ... Active Pharmaceutical Ingredients exclusively from FDA-registered manufacturers." This is consistent with 503A operation but does not foreclose 503B partnerships. 503A vs 503B specifics are not foregrounded on the homepage. Open Item.

Maximus's category breadth is broad but uneven across the categories. Selected detail:

The testosterone-cream-plus-enclomiphene fertility-preservation protocol is one of Maximus's distinctive bets. Compounded topical testosterone combined with enclomiphene is marketed as a way to elevate testosterone while preserving endogenous production (and therefore fertility) — a meaningful selling point for younger men considering TRT. Maximus has published its own whitepaper on this protocol; per our standards, that whitepaper is excluded as evidence and is recorded only as a marketing observation. The underlying clinical rationale has academic precedent, but the specific Maximus protocol is not subject to independent peer-reviewed validation.

The Oxytocin Calming Cream is the most genuinely novel product in our entire provider set. Transdermal oxytocin formulations are not a commodity offering — most other DTC providers do not carry this. Whether the novelty maps to clinical efficacy is precisely the question the Maximus whitepaper purports to answer (and the question peer-reviewed literature has not yet answered).

Maximus publishes a named medical advisory team on the homepage. The roster is unusually credentialed for the DTC space, particularly in urology, and weighted toward academic medicine rather than general telehealth practitioners.

The CEO and Co-Founder carries a PhD in Clinical Psychology (not an MD), as discussed in section 01. The remaining four advisors are described by Maximus as MDs. We cross-checked two of the four against the public NPI Registry on 10 June 2026 — both are individually registered and actively licensed, both with Urology taxonomy primary, both with named academic affiliations Maximus cites (one at Tulane Medical Center as Chief of Andrology, one at Cedars-Sinai as Assistant Clinical Professor). A third named advisor, described by Maximus as an Adjunct Associate Professor of Urology at UNC, did not return a definitive NPI match in this snapshot — the lookup is an open item. A fourth advisor, described as a hormone expert and bestselling author, was not run through NPI verification at the level required for inclusion in this review.

The verified portion of the advisory roster — two confirmed academic urologists with active practice at named top institutions — is meaningful signal for a testosterone-focused platform. The chief-of-andrology profile in particular reflects a senior academic urology presence that DTC platforms rarely engage as an advisor.

Reading the third-party signals. Maximus shows the conflict pattern familiar from the compounded-DTC set: Trustpilot positive (4.4/5 across 976 reviews), BBB negative (not accredited; F rating per Nutrition and Nourishment Collective May 2026 and Innerbody January 2026). The sample size is smaller than at Henry, Mochi, or Hims, consistent with Maximus's self-stated 50k+ member count (smaller than the GLP-1-focused peers). Independent third-party reviews from Innerbody, vaccinealliance.org, and Nutrition and Nourishment Collective all confirm the F rating directly.

Pros.

Most academically credentialed urology advisory board in our set. Two foregrounded advisors are verified senior urologists with active practice at named academic medical centers (Tulane and Cedars-Sinai). A third advisor is described as adjunct faculty at UNC (NPI verification pending).

Four testosterone delivery formats under one platform — cream, injectable, oral, and enclomiphene. Patients with different preferences and contraindications have options most competitors don't offer.

Substantial lab testing layer integrated with the testosterone protocol. The 146-marker comprehensive panel is unusual at this price point, and the testosterone-specific at-home test is appropriate for the category.

Novel oxytocin transdermal product — the only provider in our set offering this. Whether the novelty maps to clinical efficacy is unresolved, but the product itself is a category-leading bet.

LegitScript certified (seal ID 9646940).

Cons and trade-offs.

BBB rates Maximus at F, and the company is not BBB-accredited. Per Nutrition and Nourishment Collective May 2026, Innerbody (January 2026), and vaccinealliance.org (May 2026), Maximus Tribe is not a BBB Accredited Business and carries an F rating. This is the same BBB pattern as at the compounded-DTC peers (Henry, Mochi).

Self-published whitepaper layer is the primary evidence base for proprietary protocols. Maximus has published 5+ whitepapers on its own protocols (Oral TRT liver safety, Enclomiphene protocol, Topical Testosterone + Enclomiphene for fertility preservation, Oxytocin formulation). All meet the four exclusion criteria under our editorial standards. We record their existence as marketing observations; we do not propagate their numbers.

Outcome visualizations are uncited. "↑3.1× Free testosterone" and "↓28% body fat over 18 months" appear in chart-style formats suggestive of clinical-trial results, with no underlying peer-reviewed citation, no cohort size disclosure, and no timeframe specification beyond "over 18 months." Treat as marketing.

Enclomiphene as TRT is off-label and not foregrounded as such for patients. Long-term safety data is limited.

Oxytocin Calming Cream is not FDA-approved for mood/stress/sleep and rests its outcome claims on the Maximus-authored whitepaper.

The "Dr." honorific on the CEO's name may be misread as a physician credential. Maximus's CEO and Co-Founder holds a PhD in Clinical Psychology, not an MD. The "Dr." title is technically correct but the distinction warrants foregrounding for prospective patients.

Full pricing matrix is not on the static surface. Testosterone, peptide, ED, and lab pricing require per-protocol pages or onboarding-flow entry.

Compounded medications are not FDA-approved, and tirzepatide/semaglutide availability is regulation-sensitive (recheck after the FDA's 29 June 2026 comment deadline).

One of the named urology advisors (described as UNC adjunct faculty) has NPI verification pending — one of five Maximus-named medical-leadership figures.

Maximus makes the most sense for the men's-optimization-focused patient who wants testosterone-replacement therapy with academic-urology advisory backing, who is comfortable with off-label use of enclomiphene as a fertility-preserving TRT alternative, and who wants a serious lab-testing layer underpinning the protocol. It fits patients who specifically want compounded testosterone in multiple delivery formats; who are interested in trying the novel transdermal oxytocin cream and understand it's experimental for mood/stress; and who value academic credentials on the advisor side more than a large advertising or public-market presence.

Skip it if you want only FDA-approved therapies — Maximus's compounded GLP-1, compounded testosterone, compounded enclomiphene, sermorelin, and compounded oxytocin are all off-label or non-FDA-approved at the product level. Skip it if you weight peer-reviewed evidence heavily — Maximus's marketing leans on self-published whitepapers and uncited outcome visualizations rather than peer-reviewed primary trials. Skip it if you want detailed transparency on the compounded GLP-1 line — Maximus's tirzepatide and semaglutide are priced lower than most branded competitors but lack the manufacturer-direct supply story Hims and Ro have. And skip it if the "Dr." honorific on the CEO's name reads differently to you once you know the title rests on a PhD in Clinical Psychology rather than an MD.

Our editorial position is to keep head-to-head verdicts in dedicated comparison pages rather than inside any single review. The shape of Maximus's position is clear at this level.

Against the other men's-focused DTC operators (Hims), Maximus has a much deeper testosterone-format menu (Hims's testosterone surface is enclomiphene-only; Maximus offers four formats) and a more academically credentialed urology advisory board. Hims counters with NYSE-listed transparency, FDA-approved branded GLP-1, and a more diverse advisor roster outside urology (cardiology, endocrinology). Against the broad branded operators (Ro), Maximus is narrower-category but has more clinical depth in testosterone specifically. Against the compounded-DTC operators (TeleZenMD, Henry, Mochi, TrimRx), Maximus's GLP-1 line is comparable on pricing but the testosterone-focus is a meaningful differentiator. Against Henry Meds specifically on TRT, Henry includes the FDA-approved oral KYZATREX option that Maximus does not carry; Maximus has the deeper compounded format range and the academic urology advisors.

The clearest case for Maximus over any of those alternatives is wanting a testosterone-focused platform with academic-urology advisor signal, multiple format choices, and a serious lab-testing layer — knowing the trade-offs around off-label enclomiphene, the self-published whitepaper evidence base, and the compounded GLP-1 line.

How we reviewed this. Pricing, programs, and medical-leadership details were pulled directly from Maximus's public homepage and per-category nav menus in June 2026. Specific pricing for testosterone, peptides, ED, and lab testing was not on the static homepage and is listed as an open item for the next re-pull. Prescriber verification was conducted independently against the public NPI Registry for two of five Maximus-named medical-leadership figures — both Urology faculty (at Tulane Medical Center and Cedars-Sinai), individually registered and active with the credentials Maximus describes. NPI verification for two additional named advisors (one described as UNC adjunct faculty, one as a hormone-medicine author) is pending. The CEO and Co-Founder holds a PhD in Clinical Psychology, not an MD, so NPI is not applicable. Clinical claims in this review are anchored to peer-reviewed primary trials (STEP 1, SURMOUNT-1, TRAVERSE, plus FDA-approved testosterone benchmarks) and FDA primary sources; we do not propagate the "3.1× free testosterone," "28% body fat reduction," or oxytocin-cream outcome claims as evidence — they are uncited or footnoted only to Maximus-published whitepapers that meet our exclusion criteria for company-affiliated self-published studies.

Editorial independence. PeptideWellness does not accept payment from telehealth providers, compounding pharmacies, or manufacturers in exchange for coverage, placement, or scoring. We have no commercial relationship with Maximus.

Editorial note: Informational only — not medical advice. Compounded medications aren't FDA-approved and don't undergo the same safety, effectiveness, or manufacturing review as branded pharmaceuticals. Off-label use of enclomiphene as TRT and transdermal oxytocin for mood/stress/sleep carry distinct regulatory and clinical profiles. Testosterone-replacement, weight-loss, and hormone decisions should be made with a licensed healthcare provider familiar with your medical history. Last reviewed June 2026.